Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LoDoCo VRIC colchicine study in stable coronary artery disease
ACTRN12610000397011Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colchicine in coronary arteriosclerosis (2 arms), sponsored by Pfizer. Primary endpoint: Correlation of high sensitivity C-reactive protein with change in endothelial function. Started Jan 2010; status: recruiting.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12610000397011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000397011.